Save time and get answers to complex questions with AI chat
How many years does kadcyla's market exclusivity last?Patent expiration eu dabrafenib?What's the advised delay for milk post lipitor?Mebendazole for kids price?Mobic injection patent oehringer ingelheim france?
See the DrugPatentWatch profile for bosentan
Bosentan, a medication used to treat pulmonary arterial hypertension (PAH), can cause serious side effects such as liver damage and decreased blood platelets [1]. Due to these risks, it's essential to manage discontinuation carefully. According to the manufacturer's guidelines, when stopping bosentan therapy, the dose should be gradually tapered over a period of about 4 weeks, unless a more rapid discontinuation is medically justified [2]. Rapid discontinuation may lead to rebound effects, which can worsen symptoms, or increase the risk of sudden worsening of PAH symptoms [3]. For patients with serious side effects, healthcare providers often recommend temporary withholding of bosentan followed by reassessment and a possible reintroduction of a lower dose, rather than immediate discontinuation [4]. However, this decision should be made on a case-by-case basis, taking into account individual patient factors and the severity of the side effects [5]. It's essential to consult the manufacturer's guidelines for bosentan, as well as guidance from a healthcare provider, for the most up-to-date recommendations on discontinuation, especially in cases of serious side effects. Sources: [1] https://www.drugpatentwatch.com/US/DLQ9W6/ bosentan [2] https://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/021077s020lbl.pdf [3] https://www.ncbi.nlm.nih.gov/ pubmed/21398691 [4] https://www.ncbi.nlm.nih.gov/ pubmed/21666258 [5] https://www.ncbi.nlm.nih.gov/ pubmed/21454939
Other Questions About Bosentan :